Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pioglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | MPC2 | O95563 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pioglitazone SCHEMBL21843 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162192 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29759383 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29591932 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL611563 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL676871 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1489588 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4426214 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4121 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162440 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9775801-B2 | Composition and method for management of diabetes or pre-diabetes | OMNIBLEND INNOVATION PTY LTD. (AU) | 2017-10-03 | — | — | US | disclosed |
| US-20170189332-A1 | COMPOSITION AND METHOD FOR MANAGEMENT OF DIABETES OR PRE-DIABETES | OMNIBLEND INNOVATION PTY LTD (AU) | 2017-07-06 | — | — | US | disclosed |
| CN-104483445-B | A kind of thiazolidinedione quick detection kit and detection method thereof | 广东省食品药品检验所 | 2016-10-12 | — | — | CN | disclosed |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-7612058-B2 | Methods for inhibiting sterol absorption | SCHERING CORPORATION (US) | 2009-11-03 | — | — | US | disclosed |
| EP-2059241-A1 | PHARMACEUTICAL COMBINATIONS FOR LIPID MANAGEMENT AND IN THE TREATMENT OF ATHEROSCLEROSIS AND HEPATIC STEATOSIS | SCHERING CORPORATION (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1998759-A2 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20080261942-A1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1981524-A2 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV POLYMERASE INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1427409-B1 | METHODS FOR TREATING OR PREVENTING VASCULAR INFLAMMATION USING STEROL ABSORPTION INHIBITOR(S) | SCHERING CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20020183305-A1 | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2002096415-A2 | USE OF AZETIDINONE SUBSTITUTED DERIVATIVES IN THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020169134-A1 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | SCHERING CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-10-17 | — | — | US | disclosed |
| WO-2002058685-A2 | COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058732-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058733-A2 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058696-A2 | THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 203/4885RXRA 37/4885 |
| US-20080261942-A1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SLC10A2, SLC10A1, CYP46A1 | PPARG 197/4885CYP3A4 307/4885RXRA 762/4885 |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | CYP3A43, CYP3A4, CYP3A7 | PPARG 1660/4885CYP3A4 2/4885RXRA 1846/4885 |
| US-20020183305-A1 | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | CYP46A1, APOB, SLC10A2 | PPARG 219/4885CYP3A4 345/4885RXRA 190/4885 |
| US-20020169134-A1 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | CYP46A1, CYP27A1, CYP51A1 | PPARG 1488/4885CYP3A4 303/4885RXRA 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.